Zhu Zhihua, Naunton Mark, Mortazavi Reza, Bushell Mary
Discipline of Pharmacy, School of Health Sciences, Faculty of Health, University of Canberra, Canberra, ACT 2617, Australia.
Healthcare (Basel). 2024 Feb 7;12(4):428. doi: 10.3390/healthcare12040428.
Air pollution can cause numerous health problems and increase the need for medicines to treat and prevent asthma in affected areas. There is limited evidence about the association between airborne particles with a diameter of 2.5 micrometres or smaller (PM) and asthma medicine usage. This study examined the potential association between the levels of PM and the supply of prescription asthma medicines in the Australian Capital Territory (ACT), Australia, during the severe bushfire season between November 2019-January 2020.
Daily data was obtained from an ACT air quality monitoring station from November 2019 to January 2020 (study period) and November 2018 to January 2019 (control period, no bushfire). The number and types of government-funded asthma medicine prescriptions were obtained from the Services Australia (government) website by searching under 'Pharmaceutical Benefits Scheme Item Reports' and using relevant item codes during the study and control periods.
The medians for PM levels for the study period were significantly higher than those for the control period ( < 0.001). There were increases in the number of dispensed prescriptions of short-acting beta-2 agonists (SABA), inhaled corticosteroids, and long-acting beta-2 agonists combined with inhaled corticosteroids. The greatest difference was seen with the inhaled corticosteroids: a 138% increase.
The increase in the number of dispensed asthma prescriptions during the bushfire season should be used to inform the stock holdings of these medicines in preparation for future events to ensure access to lifesaving asthma medicines.
空气污染会引发众多健康问题,并增加受影响地区治疗和预防哮喘所需药物的用量。关于直径为2.5微米或更小的空气颗粒物(PM)与哮喘药物使用之间的关联,证据有限。本研究调查了2019年11月至2020年1月澳大利亚堪培拉地区(ACT)严重丛林火灾季节期间,PM水平与处方哮喘药物供应之间的潜在关联。
获取了ACT空气质量监测站在2019年11月至2020年1月(研究期)以及2018年11月至2019年1月(对照期,无丛林火灾)的每日数据。通过在澳大利亚服务局(政府)网站上搜索“药品福利计划项目报告”并使用相关项目代码,获取了研究期和对照期内政府资助的哮喘药物处方数量和类型。
研究期内PM水平的中位数显著高于对照期(<0.001)。短效β-2激动剂(SABA)、吸入性糖皮质激素以及长效β-2激动剂与吸入性糖皮质激素联合使用的配药处方数量有所增加。吸入性糖皮质激素的差异最为显著:增加了138%。
丛林火灾季节哮喘配药处方数量的增加,应用于指导这些药物的库存储备,为未来事件做好准备,以确保能够获取救命的哮喘药物。